Atricure Inc. Stock
Atricure Inc. Stock
Heavy losses for Atricure Inc. today as the stock fell by -€2.200 (-6.360%).
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Atricure Inc..
As a result the target price of 44 € shows a positive potential of 35.8% compared to the current price of 32.4 € for Atricure Inc..
Pros and Cons of Atricure Inc. in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | -6.360% | -0.613% | 18.248% | -47.742% | -4.706% | -47.742% | -54.366% |
| Orthofix Medical Inc. | 0.000% | 4.188% | 18.452% | 6.417% | -22.868% | -43.143% | -69.665% |
| Lantheus Holdings Inc | 1.390% | -3.618% | -10.031% | 44.098% | 53.671% | 31.626% | - |
| Cerus Corp. | 0.540% | -27.519% | -32.734% | 66.075% | 6.735% | -15.955% | -56.713% |
Comments
AtriCure (ATRC) was given a new $50.00 price target by UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (ATRC) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (ATRC) was upgraded by Freedom Capital to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
News
AtriCure Q2 Earnings Call Highlights
Key Points
- Interested in AtriCure, Inc.? Here are five stocks we like better.
- AtriCure posted strong Q2 2026 results, with revenue up 12.8% to $153.6 million and a return to GAAP
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
This medical device innovator for cardiac surgery reported an insider sale amid a year of negative total returns.
Doraiswamy Vinayak, Chief Scientific Officer of AtriCure (NASDAQ:ATRC), reported the
